Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company filings document formal disclosures for an operating consumer-products issuer with a portfolio of household, food, grilling, pet-care, water-filtration and personal-care brands. Its Form 8-K reports include quarterly operating and financial results, supplemental financial information, outlook-related materials and Regulation FD disclosures tied to the company's reported performance.
Clorox filings also record governance and capital-market matters, including shareholder meeting results, director elections, advisory executive-compensation votes, auditor ratification, executive transition disclosures, material-event reports, material agreements, capital-structure disclosures and risk-factor updates when applicable. These records connect the company's brand portfolio, completed acquisitions and public-company governance to its SEC reporting obligations.
The Clorox Company reported softer results for the quarter ended December 31, 2025. Net sales slipped to $1.67 billion, down 1% from a year ago, as lower consumption in several U.S. categories offset growth internationally. Gross profit was $722 million, with gross margin easing to 43.2% from 43.8% on higher manufacturing and logistics costs despite ongoing cost savings.
Net earnings attributable to Clorox fell to $157 million from $193 million, and diluted EPS declined 16% to $1.29, reflecting lower gross profit and lapping prior-period cyberattack insurance recoveries and tax benefits. For the first six months, net sales decreased 10% to $3.10 billion and diluted EPS dropped 18% to $1.93, pressured by lower shipments following last year’s ERP-related inventory build and the divestiture of the Better Health VMS business.
Operating cash flow remained solid at $404 million for the six-month period. Clorox plans two significant cash uses: a $476 million purchase of Procter & Gamble’s 20% interest in the Glad venture and a definitive agreement to acquire GOJO Industries for approximately $2.25 billion in cash, to be funded primarily with debt, subject to regulatory approval and customary closing conditions.
The Clorox Company reported softer results for the quarter ended December 31, 2025. Net sales slipped to $1.67 billion, down 1% from a year ago, as lower consumption in several U.S. categories offset growth internationally. Gross profit was $722 million, with gross margin easing to 43.2% from 43.8% on higher manufacturing and logistics costs despite ongoing cost savings.
Net earnings attributable to Clorox fell to $157 million from $193 million, and diluted EPS declined 16% to $1.29, reflecting lower gross profit and lapping prior-period cyberattack insurance recoveries and tax benefits. For the first six months, net sales decreased 10% to $3.10 billion and diluted EPS dropped 18% to $1.93, pressured by lower shipments following last year’s ERP-related inventory build and the divestiture of the Better Health VMS business.
Operating cash flow remained solid at $404 million for the six-month period. Clorox plans two significant cash uses: a $476 million purchase of Procter & Gamble’s 20% interest in the Glad venture and a definitive agreement to acquire GOJO Industries for approximately $2.25 billion in cash, to be funded primarily with debt, subject to regulatory approval and customary closing conditions.
The Clorox Company reported softer results for the quarter ended December 31, 2025. Net sales slipped to $1.67 billion, down 1% from a year ago, as lower consumption in several U.S. categories offset growth internationally. Gross profit was $722 million, with gross margin easing to 43.2% from 43.8% on higher manufacturing and logistics costs despite ongoing cost savings.
Net earnings attributable to Clorox fell to $157 million from $193 million, and diluted EPS declined 16% to $1.29, reflecting lower gross profit and lapping prior-period cyberattack insurance recoveries and tax benefits. For the first six months, net sales decreased 10% to $3.10 billion and diluted EPS dropped 18% to $1.93, pressured by lower shipments following last year’s ERP-related inventory build and the divestiture of the Better Health VMS business.
Operating cash flow remained solid at $404 million for the six-month period. Clorox plans two significant cash uses: a $476 million purchase of Procter & Gamble’s 20% interest in the Glad venture and a definitive agreement to acquire GOJO Industries for approximately $2.25 billion in cash, to be funded primarily with debt, subject to regulatory approval and customary closing conditions.
The Clorox Company filed a current report to note that it issued a press release with its financial results for the second quarter ended December 31, 2025. The press release is provided as Exhibit 99.1, and additional supplemental financial information is included as Exhibit 99.2.
The Clorox Company filed a current report to note that it issued a press release with its financial results for the second quarter ended December 31, 2025. The press release is provided as Exhibit 99.1, and additional supplemental financial information is included as Exhibit 99.2.
The Clorox Company filed a current report to note that it issued a press release with its financial results for the second quarter ended December 31, 2025. The press release is provided as Exhibit 99.1, and additional supplemental financial information is included as Exhibit 99.2.
The Clorox Company plans to acquire GOJO, maker of PURELL, by purchasing all of GOJO’s membership interests for $2.25 billion in cash, subject to customary adjustments and including anticipated tax benefits valued at approximately $330 million. Clorox expects to fund the deal primarily with debt financing, and completion will depend on regulatory approval and other customary closing conditions.
Alongside the transaction announcement, Clorox posted an investor presentation and issued a press release that reaffirms its fiscal 2026 outlook for net sales, diluted EPS and adjusted EPS. The company also outlines numerous risks and uncertainties that could affect the closing of the acquisition, integration of GOJO and the expected financial and strategic benefits.
The Clorox Company plans to acquire GOJO, maker of PURELL, by purchasing all of GOJO’s membership interests for $2.25 billion in cash, subject to customary adjustments and including anticipated tax benefits valued at approximately $330 million. Clorox expects to fund the deal primarily with debt financing, and completion will depend on regulatory approval and other customary closing conditions.
Alongside the transaction announcement, Clorox posted an investor presentation and issued a press release that reaffirms its fiscal 2026 outlook for net sales, diluted EPS and adjusted EPS. The company also outlines numerous risks and uncertainties that could affect the closing of the acquisition, integration of GOJO and the expected financial and strategic benefits.
The Clorox Company director reports new deferred stock units tied to CLX common stock. A Form 4 filing shows acquisitions of derivative securities classified as deferred stock units on several 2025 dates. These units convert into Clorox common stock on a 1-for-1 basis.
The director acquired 227.0333 deferred stock units on 11/06/2025 and additional amounts of 1,637.8577 and 272.7363 deferred stock units on 12/31/2025, all at a price of $0.0000 per unit. Following these transactions, the director directly beneficially owns 21,596.5756 deferred stock units.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent an annual award under the 2005 Stock Incentive Plan, and others reflect electing to receive quarterly director fees in deferred stock units. These units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.
Clorox Company director equity compensation and fee deferral is reported in this insider trading disclosure. The filing shows several awards of deferred stock units, each representing the right to receive an equal number of Clorox common shares.
On 11/06/2025, the director acquired 179.1424 deferred stock units at an exercise price of $0.0000, bringing the balance to 15,533.383 units held directly. On 12/31/2025, the director acquired an additional 1,637.8577 deferred stock units and a further 334.7218 units, increasing direct holdings to about 17,505.9625 deferred stock units.
The disclosure notes that some units were obtained through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, others as the annual deferred stock unit award under the 2005 Stock Incentive Plan, and others received instead of quarterly director cash fees. The units will be settled 100% in Clorox stock upon the director’s retirement or other termination of board service.
The Clorox Company director reports additional deferred stock units related to board compensation and dividend reinvestment. On November 6, 2025, the director acquired 199.1684 deferred stock units, each convertible into one share of Clorox common stock, at a price of $0.0000 per unit, bringing the total beneficially owned to 17,269.8302 units.
On December 31, 2025, the director received an additional 1,637.8577 deferred stock units as an annual award and 520.6784 deferred stock units in lieu of quarterly director fees, increasing total holdings to 19,428.3663 deferred stock units. These units are credited under Clorox’s independent director compensation plans and will be settled in Clorox stock when the director retires or otherwise leaves the board.
The Clorox Company director reported several deferred stock unit transactions. On 11/06/2025, the director acquired 63.1574 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan on a 1-for-1 basis with Clorox common stock. On 12/31/2025, the director received 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, and 272.7363 deferred stock units in lieu of quarterly director fees. All units have an exercise price of $0.0000 and each unit represents one share of Clorox common stock. Following these transactions, the director beneficially owns 7,386.9498 deferred stock units, which will be settled in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. (CLX) disclosed a Form 4 for a director reporting routine deferred stock unit activity during 2025. The filing shows multiple acquisitions of deferred stock units tied to Clorox common stock, including 74.9914 units on 02/14/2025, 82.9936 on 05/09/2025, 97.043 on 08/29/2025, 109.0592 on 11/06/2025, and an annual award of 1,637.8577 units on 12/31/2025, all at a price of $0.0000.
After these transactions, the director beneficially owns 11,094.3468 deferred stock units directly. The units are credited on a 1-for-1 basis and will be settled 100% in Clorox stock in connection with the director’s retirement or other termination of service. Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and the year-end grant was made under the 2005 Stock Incentive Plan.
The Clorox Company director reported routine equity compensation activity in the form of deferred stock units. The filing shows several acquisitions of deferred stock units tied to Clorox common stock during 2025, including transactions dated 02/14/2025, 05/09/2025, 08/29/2025, 11/06/2025, and 12/31/2025. These awards were recorded at an exercise price of $0.0000 per unit.
The director’s beneficial holdings in these derivative securities increased to 15,677.4328 deferred stock units held directly. The explanation notes that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, while an additional annual award was granted under the 2005 Stock Incentive Plan. Each deferred stock unit represents a 1-for-1 right to receive Clorox stock, to be settled in shares upon the director’s retirement or other termination of service from the board.
The Clorox Company director reports routine deferred stock awards. A board member of Clorox (ticker CLX) reported several grants of deferred stock units that each convert 1-for-1 into Clorox common stock. On 11/06/2025, the director acquired 219.3396 deferred stock units, bringing the beneficial holding to 19,018.8638 units. On 12/31/2025, additional awards of 1,219.1572 and 145.2617 deferred stock units increased the total to 20,383.2827 units held directly.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent the annual deferred stock unit award under the 2005 Stock Incentive Plan, and some reflect stock units received instead of a portion of quarterly director fees. All deferred stock units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.